Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan…
Browsing: Moderna Inc
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of…
The Company’s ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to…
Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the…
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna’s Enterprise Solutions Hubs in…
Announcement follows recent authorization of the Company’s mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active…
Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration…
Announcement reinforces Moderna’s commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia,…